Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K3QS
|
|||
| Former ID |
DAP001223
|
|||
| Drug Name |
Everolimus
|
|||
| Synonyms |
Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Approved | [1], [2] | |
| Kidney cancer [ICD-11: 2C90.0; ICD-9: 189] | Phase 3 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C53H83NO14
|
|||
| Canonical SMILES |
CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
|
|||
| InChI |
1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
|
|||
| InChIKey |
HKVAMNSJSFKALM-GKUWKFKPSA-N
|
|||
| CAS Number |
CAS 159351-69-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12014881, 14767667, 14865574, 50044230, 50112765, 56311446, 56312241, 56312580, 56313164, 91613187, 104178966, 134338463, 135156085, 136340120, 136929859, 137140572, 139754909, 143493384, 144206063, 151990396, 152236848, 152258132, 160645716, 160646971, 162189189, 174527790, 175265707, 177748738, 179150022, 203355779, 226396389
|
|||
| ChEBI ID |
CHEBI:68478
|
|||
| ADReCS Drug ID | BADD_D00858 | |||
| SuperDrug ATC ID |
L01XE10; L04AA18
|
|||
| SuperDrug CAS ID |
cas=159351696
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5889). | |||
| REF 2 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | |||
| REF 3 | Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.